Overview: HIV-2 RNA Quantitative Panel
Introduction: The HIV-2 RNA Quantitative Panel is a diagnostic tool designed to quantify HIV-2 viral load using whole blood samples. In India, HIV-2 infection is rare (~1-2 percent of HIV cases, higher in western/southern states), with slower progression but resistance to some ART (NNRTIs). Viral load monitoring is essential for confirming active infection and treatment response. High morbidity from under-testing in regions with dual HIV-1/2 prevalence, limited HIV-2 specific labs, delayed appropriate ART leading to virologic failure. Per microbiology practices aligned with NACO and WHO guidelines, the test employs PCR for HIV-2 RNA quantitative over 1-2 days with high accuracy, valuable for monitoring in HIV-2 mono or dual infection. This diagnostic falls under viral load monitoring and targets patients with HIV-2 diagnosis or risk, addressing accurate detection to guide protease inhibitor-based therapy. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise viremia assessment and reducing HIV-2 complications. Its whole blood-based approach ensures reliable viral load quantification.
Other Names: HIV-2 RNA Pnl.
FDA Status: FDA approved, CLIA certified for microbiology/immunology/hematology, compliant with 2025 standards.
Historical Milestone: HIV-2 RNA quantitative; in India, used in high-prevalence areas.
Purpose: The test assesses 3 parameters including HIV-2 RNA quantitative to guide viral load monitoring, assess active infection, inform therapy.
Test Parameters: 1. HIV-2 RNA Quantitative, 2. Viral Load, 3. Total Lymphocytes.
Pretest Condition: No fasting required; patients should have confirmed HIV-2.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell/RNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable for flow; RNA stable frozen.
Medical History: Patients should provide details on HIV-2 diagnosis, treatment, symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of poor monitoring including progression, benefits of assessment, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Detectable viral load indicates active replication, necessitating specialist input.
Specialist Consultation: HIV specialists should be consulted for management.
Additional Supporting Tests: HIV-1/2 differentiation for confirmation.
Test Limitations: HIV-2 specific; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, HIV Studies India 2023.
